BridgeBio Pharma (NASDAQ:BBIO) Posts Earnings Results, Misses Estimates By $0.14 EPS

BridgeBio Pharma (NASDAQ:BBIO) released its quarterly earnings data on Thursday. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.14), FiscalAI reports. The firm had revenue of $194.52 million for the quarter, compared to analysts’ expectations of $178.64 million. BridgeBio Pharma’s revenue was up 66.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.88) EPS.

Here are the key takeaways from BridgeBio Pharma’s conference call:

• Attruby (acoramidis) delivered $180.6 million in U.S. net product revenue in Q1 (24% QoQ, 392% YoY), with accelerating front?line share and emerging real?world evidence showing clinical differentiation versus tafamidis (including reduced diuretic intensification and signals of lower acute kidney injury and mortality).
• BridgeBio is preparing three near?term launches (LGMD2I/BBP?418, ADH1/encaleret, and achondroplasia/infigratinib) with rapid NDA submission for LGMD2I, active patient?identification efforts (?2,000 ADH1 candidates by claims), and strong commercial readiness and early awareness for infigratinib.
• The board authorized a $500 million share repurchase program to address a perceived disconnect between intrinsic value and market price, while management says repurchases will be opportunistic and preserve capital for launches and development.
• Q1 results show revenue growth (total revenue $194.5M) driven by Attruby, an improving operating loss trajectory (Q1 operating loss $106M, narrowing over recent quarters), and a strong liquidity position ($940.2M in cash and marketable securities) with guidance toward P&L breakeven and sustainable cash flow positivity by and after 2027.

BridgeBio Pharma Stock Performance

NASDAQ BBIO traded down $0.06 on Friday, reaching $67.39. 5,401,164 shares of the stock traded hands, compared to its average volume of 2,774,435. BridgeBio Pharma has a 12 month low of $31.77 and a 12 month high of $84.94. The company has a market cap of $13.20 billion, a price-to-earnings ratio of -17.83 and a beta of 1.02. The company has a fifty day moving average price of $71.27 and a 200-day moving average price of $71.32.

BridgeBio Pharma News Roundup

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: BridgeBio reported Q1 revenue of about $194.5 million, beating estimates and showing 66.8% year-over-year growth, helped by continued commercial progress for Attruby. BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates
• Neutral Sentiment: The company approved inducement grants of restricted stock units for 52 new employees, which supports hiring and retention but also adds modest share-based dilution over time. BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
• Neutral Sentiment: BridgeBio is also drawing attention after a new $500 million ATM program was filed, giving it additional financing flexibility but potentially increasing future share supply. BridgeBio Pharma Launches New $500 Million ATM Program
• Negative Sentiment: Despite the revenue beat, Q1 EPS was a loss of $0.84 per share, wider than the $0.70 loss expected, reinforcing concerns that profitability remains elusive. BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates

Insider Buying and Selling at BridgeBio Pharma

In other news, CAO Maricel Apuli sold 2,000 shares of the firm’s stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $71.58, for a total transaction of $143,160.00. Following the transaction, the chief accounting officer owned 134,115 shares in the company, valued at approximately $9,599,951.70. This trade represents a 1.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Andrea Ellis sold 64,921 shares of BridgeBio Pharma stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $64.87, for a total value of $4,211,425.27. Following the completion of the sale, the director owned 18,589 shares of the company’s stock, valued at $1,205,868.43. The trade was a 77.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 239,084 shares of company stock worth $16,777,579. Insiders own 14.23% of the company’s stock.

Hedge Funds Weigh In On BridgeBio Pharma

Hedge funds and other institutional investors have recently modified their holdings of the business. Jones Financial Companies Lllp bought a new position in BridgeBio Pharma in the first quarter worth approximately $35,000. First Trust Advisors LP increased its holdings in shares of BridgeBio Pharma by 200.4% in the 2nd quarter. First Trust Advisors LP now owns 263,693 shares of the company’s stock valued at $11,386,000 after acquiring an additional 175,918 shares during the period. Baird Financial Group Inc. raised its position in shares of BridgeBio Pharma by 1.8% in the 2nd quarter. Baird Financial Group Inc. now owns 42,057 shares of the company’s stock worth $1,816,000 after acquiring an additional 731 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main bought a new position in shares of BridgeBio Pharma in the 2nd quarter worth $1,650,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in BridgeBio Pharma by 2.4% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 95,326 shares of the company’s stock valued at $4,132,000 after purchasing an additional 2,206 shares during the last quarter. 99.85% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently issued reports on BBIO. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BridgeBio Pharma in a report on Wednesday, January 21st. Barclays reiterated an “overweight” rating on shares of BridgeBio Pharma in a research report on Tuesday, March 10th. Truist Financial boosted their price objective on shares of BridgeBio Pharma from $95.00 to $102.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. Leerink Partners reiterated an “outperform” rating and issued a $98.00 price target on shares of BridgeBio Pharma in a report on Thursday, March 12th. Finally, Oppenheimer reduced their target price on BridgeBio Pharma from $83.00 to $81.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 25th. Twenty-four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $87.71.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.